Lahiri Shawon, Sen Tuhinadri, Palit Gautam
Neuropharmacology Unit, Division of Pharmacology, Central Drug Research Institute, Lucknow-226001, UP, India.
Eur J Pharmacol. 2009 May 1;609(1-3):118-25. doi: 10.1016/j.ejphar.2009.03.005. Epub 2009 Mar 10.
Evidences suggest Peroxisome Proliferator Activated Receptor-gamma (PPAR-gamma) ligand, pioglitazone results in the attenuation of gastric mucosal injury. But the molecular mechanism through which these agonists actually elicit gastroprotection through modulating inflammatory responses has not yet been established. Chronic gastric ulcer induced in rats by intraluminal application of acetic acid resulted in elevation of proinflammatory cytokines gene expression, such as, TNF-alpha (Tumor Necrosis Factor-alpha), IL-1beta (Interleukin-1beta) and the protein levels of nuclear p65 subunit of NF-kappaB (Nuclear Factor-kappaB) but decreased levels of PPAR-gamma gene expression. Pioglitazone treatment reduced the severity of ulceration, repressed levels of TNF-alpha, IL-1beta and nuclear p65 subunit as well as increased the abundance of PPAR-gamma in gastric mucosa. Moreover, it significantly upregulated protein levels of glucocorticoid receptor demonstrating its possible involvement in pioglitazone mediated ulcer healing along with PPAR-gamma. Administration of pioglitazone reverted back the decreased levels of both PPAR-gamma and glucocorticoid receptor, resulting in their redistribution to the nucleus from the cytosol in course of ulcer healing. Moreover, pharmacological inhibition of glucocorticoid receptor function by its antagonist (RU486) inhibited pioglitazone mediated downregulation of TNF-alpha and IL-1beta gene expression confirming involvement of glucocorticoid receptor in pioglitazone mediated ulcer healing. Co-immunoprecipitation studies further established association of PPAR-gamma with glucocorticoid receptor during ulcer healing which was enhanced following pioglitazone administration. Thus, the present study is first of its kind bearing direct relevance to the participation of both PPAR-gamma and glucocorticoid receptor and their physical association in influencing amelioration of inflammatory responses during pioglitazone mediated gastric ulcer healing.
有证据表明,过氧化物酶体增殖物激活受体γ(PPAR-γ)配体吡格列酮可减轻胃黏膜损伤。但这些激动剂通过调节炎症反应实际引发胃保护作用的分子机制尚未明确。大鼠经腔内注射乙酸诱导慢性胃溃疡,导致促炎细胞因子基因表达升高,如肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β),以及核因子κB(NF-κB)的核p65亚基蛋白水平升高,而PPAR-γ基因表达水平降低。吡格列酮治疗可减轻溃疡严重程度,降低TNF-α、IL-1β和核p65亚基水平,并增加胃黏膜中PPAR-γ的丰度。此外,它还显著上调糖皮质激素受体蛋白水平,表明其可能与PPAR-γ一起参与吡格列酮介导的溃疡愈合。给予吡格列酮可使PPAR-γ和糖皮质激素受体水平恢复降低状态,导致它们在溃疡愈合过程中从细胞质重新分布到细胞核。此外,用其拮抗剂(RU486)对糖皮质激素受体功能进行药理抑制,可抑制吡格列酮介导的TNF-α和IL-1β基因表达下调,证实糖皮质激素受体参与吡格列酮介导的溃疡愈合。免疫共沉淀研究进一步证实,在溃疡愈合过程中PPAR-γ与糖皮质激素受体存在关联,吡格列酮给药后这种关联增强。因此,本研究首次直接涉及PPAR-γ和糖皮质激素受体及其物理关联在吡格列酮介导的胃溃疡愈合过程中影响炎症反应改善方面的作用。